Researchers have shown that PGRMC1 contributes to doxorubicin-induced chemoresistance in uterine sarcoma [4] and PGRMC1 knockdown increases the sensitivity of colon and liver cancers to erlotinib treatment [25]. This evidence concerns the gene PGRMC1 and uterine corpus sarcoma.